(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 2 September 2010 (02.09.2010) WO 2010/099542 A2 (51) International Patent Classification: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, A61K 9/08 (2006.01) A61K 31/7076 (2006.01) DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, A61K 31/70 (2006.01) A61K 47/48 (2006.01) HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (21) International Application Number: ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, PCT/US2010/025787 NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (22) International Filing Date: SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, 1 March 2010 (01 .03.2010) TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (26) Publication Language: English GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (30) Priority Data: ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, 61/156,263 27 February 2009 (27.02.2009) US TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (71) Applicant (for all designated States except US): DUSKA MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, SCIENTIFIC CO. [US/US]; 1735 Market St. Suite TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, A408, Philadelphia, PA 19 103-7502 (US). ML, MR, NE, SN, TD, TG). (72) Inventor; and Declarations under Rule 4.17: (75) Inventor/Applicant (for US only): PELLEG, Amir [US/ — as to applicant's entitlement to apply for and be granted US]; 24 Dartmouth Lane, Haverford, PA 19041 -1020 a patent (Rule 4.1 7(H)) (US). — as to the applicant's entitlement to claim the priority of (74) Agents: BRENNAN, Jack et al; Fish & Richardson the earlier application (Rule 4.1 7(Hi)) P.C., P.O. Box 1022, Minneapolis, MN 55440-1022 (US). Published: (81) Designated States (unless otherwise indicated, for every — without international search report and to be republished kind of national protection available): AE, AG, AL, AM, upon receipt of that report (Rule 48.2(g)) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (54) Title: FORMULATIONS OF ATP AND ANALOGAS OF ATP Figure 1. (57) Abstract: This disclosure provides solutions and compositions (e.g., pharmaceutical solutions and compositions) containing adenosine 5 '-triphosphate (ATP) or an analog thereof. In addition, it features methods of making and using the solutions and compositions. Formulations of ATP and Analogs of ATP CROSS REFERENCE TO RELATED APPLICATIONS This application claims priority of U.S. Provisional Application No. 61/156,263, filed February 27, 2009, the entire disclosure of which is incorporated herein by reference in its entirety. TECHNICAL FIELD This invention relates to compositions containing adenosine 5'-triphosphate (ATP), or analogs thereof, and more particularly to pharmaceutical compositions containing ATP or analogs thereof. BACKGROUND Many therapeutic, prophylactic, and diagnostic uses for ATP, or analogs thereof, have been developed. There is a need for stable liquid pharmaceutical formulations of ATP and analogs thereof in which their pharmacological activity is maintained. SUMMARY This disclosure is based on the findings of the inventors that an alkaline solution of ATP is stable for at least six years. The disclosure features stable solutions and pharmaceutical compositions containing ATP, or an analog thereof, and methods of making and using such solutions and pharmaceutical compositions. More specifically, the disclosure provides a first aqueous solution containing: an aqueous solvent; an adenosine 5-triphosphate (ATP) reagent; and glycine, the solution having a pH of between about 8.7 and about 9.5. Another aspect of the disclosure is a second aqueous solution that contains: an aqueous solvent; and an ATP reagent, the solution having a pH of about 8.7 to about 9.5 and being formulated for administration to a subject or for contacting a mammalian cell with the ATP reagent. Also featured by the disclosure is a third aqueous solution containing: an aqueous solvent; and ATP, the solution having a pH of between about 8.7 and about 9.5. The solution is such that, at the end of a period of time at about 4°C to about 8°C, it contains an amount of ADP that is not more than about 5.0 % (e.g., not more than about 4.0 %, not more than about 3.0%, or not more than about 2.5%) of the amount of ATP in the solution, the period of time being up to six years after the solution was made. In the solutions of the disclosure the ATP reagent can be ATP or a pharmaceutically acceptable salt thereof. It can also be an ATP analog or a pharmaceutically acceptable salt thereof. The second and third aqueous solutions can further contain glycine. The pH of any of solutions of the disclosure can be between about 8.7 and about 9.4, e.g., about 8.8 and about 9.3. Moreover, any of the solutions can further contain a biocompatible buffer, e.g., a phosphate buffer such as a phosphate buffer that contains Na HPC and/or K2HPO4. The biocompatible buffer can also be a bicarbonate buffer, an acetate buffer, a citrate buffer, or a glutamate buffer. In addition, any of the solutions can contain one or more of 1,3- Bis[tris(hydroxymethyl)methylamino]propane (Bis-Tris Propane); Tris(hydroxy)aminomethane (Tris); Tris(hydroxymethyl)aminomethane (Trizma); 4-(2-Hy droxyethyl)- 1- piperazinepropanesulfonic acid (EPPS); N-[Tris(hydroxymethyl)methyl] glycine (Tricine); glycine; Diglycine (Gly-Gly); N,N-Bis(2-hydroxyethyl)glycine (Bicine); N-(2- Hydroxyethyl)piperazine-N'-(4-butanesulfonic acid) (HEPBS); N-[Tris(hydroxymethyl)methyl]- 3-aminopropanesulfonic acid (TAPS); 2-Amino-2-methyl-l,3-propanediol (AMPD); N- tris(Hydroxymethyl)methyl-4-aminobutanesulfonic acid (TABS); N-(l,l-Dimethyl-2- hydroxyethyl)-3-amino-2-hydroxypropanesulfonic acid (AMPSO); 2- (Cyclohexylamino)ethanesulfonic acid (CHES); 3-(Cyclohexylamino)-2-hy droxy- 1- propanesulfonic acid (CAPSO); or β-Aminoisobutyl alcohol (AMP). Any of the solutions can further contain a stabilizer. The stabilizer can be a chelating agent, e.g., ethylenediaminetetraacetic acid (EDTA) or ethylene glycol tetraacetic acid (EGTA). The stabilizer can also be a sugar alcohol (e.g., sorbitol, mannitol, adonitol, erythritol, xylitol, lactitol, isomalt, maltitol, or a cyclitol), glycerol, methionine, or creatinine. The ATP analog in any of the solutions can be: α,β-methylene-ATP (α,βmATP); β,γ- methylene-ATP (β,γmATP); 2-thio-ATP (2-SH-ATP); 2-methylthio-ATP (2-MeS-ATP); 2',3'-O- 2,4,6,-trinitrophenyl-ATP (TNP-ATP); 2',3'-0-(4-benzoyl)-ATP (BzATP); an N-alkyl-2 ATP; β γ adenosine 5'-( , -imido)triphosphate (AMP-PNP); ATP-MgCl 2; or oxidized ATP (oATP). The concentration of ATP, or the analog thereof, in the solutions can be about 18.15 mM or about 36.30 mM. The concentration of glycine can be about 13.32 mM. The solution can be one that includes: 18.15 mM ATP; and Na HPO Any of the solutions can be formulated for parenteral administration to a subject, e.g., for administration to a subject by injection. Alternatively, the solutions can be formulated for intravenous administration, for enteral (e.g, oral) administration, for topical administration, or for transdermal administration to a subject. In another embodiment, the disclosure provides a method of making an aqueous solution. The method includes: mixing together water, glycine, and an ATP reagent to create a mixture; and adjusting the pH of the mixture to between about 8.7 to about 9.5 to create the solution. The method can further involve mixing into the mixture a biocompatible buffer and/or mixing into the mixture a stabilizer. The pH can be adjusted by adding a base, e.g., sodium hydroxide, to the mixture. The method can also further include storing the solution at a temperature of between about 4°C and about 8°C for a period of time of up to six years. Where the ATP reagent is ATP, at the end of the period of time, the solution can contain an amount of ADP that is not more than about 5.0 % of the amount of ATP in the solution. Another aspect of the disclosure is an in vitro method of delivering an ATP reagent to a mammalian cell. The method includes incubating the cell with a medium that contains any of the above solutions in vitro. The mammalian cell can be, for example, a spermatozoon. Also provided by the invention is an in vivo method of contacting a mammalian cell in a mammalian subject with an ATP reagent. The method includes administering a composition containing or being any of the solutions disclosed herein to the subject, e.g., a human subject. The method can be a therapeutic method, a prophylactic method, or a diagnostic method. In the method, the subject can have, be suspected of having, or be at risk of developing a condition selected from an obstructive pulmonary disease (OPD), asthenozoospermia, pain, tissue injury, nerve damage, organ failure, a condition requiring reduction in blood pressure, pulmonary hypertension, tachycardia, myocardial ischemia, coronary artery disease, cystic fibrosis, cancer, and cancer-related cachexia. The cell can be a neuron (e.g., a retinal neuron, a cortical neuron, a hippocampal neuron, a basal ganglion neuron, a spinal cord neuron, a pulmonary vagal C fiber, or a pulmonary vagal A fiber), a spermatozoon, a vascular smooth muscle cell, or a vascular endothelial cell.